Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck


Por: Szturz, P, Fuereder, T, Guo, Y, Licitra, L, Mesia, R, Ivanyi, P, Falco, A, Tahara, M, Solbes, MN, Venturini, F and Bossi, P

Publicada: 1 abr 2025 Ahead of Print: 1 mar 2025
Resumen:
Treatment options for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have evolved over the past decade and have helped improve survival outcomes for patients. Most national and regional guidelines recommend first-line therapy with an immune checkpoint inhibitor (with or without chemotherapy) or a cetuximab-based regimen, by assessment of expression levels of the biomarker programmed cell death-ligand 1 (PD-L1). However, patient- and tumor-specific factors, including the patient's age, comorbidities, performance status, and tumor burden, kinetics and spread also need to be considered to optimize treatment in the first line. Additionally, with increasing availability of newer therapies globally, it is crucial to customize the subsequent second- or later-line therapy based on patient characteristics, including the previous therapy received. This review highlights the factors that should be considered for treatment decisionmaking in patients with R/M SCCHN. It also summarizes the current evidence for clinical outcomes based on treatment sequencing and provides guidance on choosing an optimal treatment regimen for patients in the firstline treatment setting and beyond.

Filiaciones:
Szturz, P:
 Univ Lausanne UNIL, Dept Oncol, Rue Bugnon 46, CH-1011 Lausanne, Switzerland

Fuereder, T:
 Lausanne Univ Hosp CHUV, Rue Bugnon 46, CH-1005 Lausanne, Switzerland

Guo, Y:
 Med Univ Vienna, Dept Med 1, Div Oncol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria

Licitra, L:
 Tongji Univ, Sch Med, Shanghai East Hosp, Dept Oncol, 1800 Yuntai Rd, Shanghai 200123, Peoples R China

 Fdn IRCCS Ist Nazl Tumori Milan, Via Giacomo Venezian, 1, I-20133 Milan, Italy

:
 Univ Milan, Via Festa Perdono,7, I-20122 Milan, Italy

Ivanyi, P:
 Inst Invest Ciencies Salut Germans Trias & Pujol I, Catalan Inst Oncol ICO, Med Oncol Dept, Badalona Appl Res Grp Oncol B ARGO Grp, Ctra Can Ruti,Cami de les Escoles,S N, Badalona 08916, Spain

Falco, A:
 Hannover Med Sch, Claudia Schilling Comprehens Canc Ctr, Dept Hematol Hemostasis Oncol & Stem Cell Transpla, Carl Neuberg Str 1, D-30625 Hannover, Germany

Tahara, M:
 Alexander Fleming Canc Inst, Dept Med Oncol, Head & Neck Unit, Cramer 1180,C1426, Autonoma Buenos Aires, Argentina

Solbes, MN:
 Natl Canc Ctr Hosp East, Dept Head & Neck Med Oncol, 6 Chome-5-1, Kashiwa, Chiba 2778577, Japan

Venturini, F:
 Merck Healthcare KGaA, Frankfurter Str 250, D-64293 Darmstadt, Germany

 Merck KGaA, Merck Serono SpA, Piazza Pigneto 9, Rome, Italy

Bossi, P:
 Humanitas Univ, IRCCS Human Res Hosp, Dept Biomed Sci, Via Rita Levi Montalcini,4, I-20072 Milan, Italy
ISSN: 03057372





Cancer Treatment Reviews
Editorial
W. B. Saunders Co., Ltd., THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Review
Volumen: 135 Número:
Páginas: 102910-102910
WOS Id: 001444805200001
ID de PubMed: 40068239
imagen Green Submitted, Green Published, hybrid

MÉTRICAS